There is no universal figure for how long compounded tirzepatide lasts. Dating belongs to the pharmacy that prepared the vial, printed on the label of that specific batch. The reason no general answer exists is that too many variables move underneath it. Understanding which variables move, and in which direction, is more useful than any number.
Compounded and approved products sit on different foundations
An FDA-approved injection reaches patients with an expiration date supported by manufacturer stability testing submitted during review. Compounded preparations are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing. Their dating comes from the compounding pharmacy, tied to what that pharmacy actually made. Change the preparation and the dating changes with it, which is why copying a figure between products is meaningless.
Because so much rides on which pharmacy actually made the vial, the provider standing in front of that pharmacy matters as much as any single risk factor. Disclosure varies from one service to the next. Ro and Henry Meds present their programs mainly around access and pricing, Sesame lists individual clinician visits, and a provider like HealthRX runs a reference page on compounded tirzepatide that lays out how the preparation is sourced and dated. Weighing that openness early is easier than reconstructing it after a shipment raises a question.
Formulation differences are the largest variable
Two pharmacies can label vials with the same drug name and produce genuinely different products. Concentration differs. Excipients differ. Buffer choice and pH differ, and those are not cosmetic details. Analytical work on semaglutide using high-resolution mass spectrometry has shown that pH, buffer composition, molarity and temperature all drive solution-state degradation. Research comparing follow-on GLP-1 polypeptide preparations found that manufacturing and compounding processes affect the properties and quality of the finished product.
Whether the product ships as a solution or as a powder requiring reconstitution changes the picture again. Stability studies on lyophilized peptide formulations, including teriparatide after reconstitution, document changes that only begin once liquid is added. A powder and a solution answer different questions and cannot inherit each other’s dating.
Preservative status decides what a vial tolerates
Whether a container is intended for repeated entry depends on whether it was formulated with an antimicrobial preservative, a decision the compounding pharmacy makes and states on the label. Preservative systems are a studied part of multi-dose product design, and their presence or absence is not visible in the liquid. A vial holding several doses of volume is not thereby a multi-dose vial. Treating it as one, when it was not made as one, introduces contamination risk that has nothing to do with the molecule.
Physical handling degrades peptides in ways nobody sees
Peptide products are physically fragile in a specific sense. Heat drives chemical degradation. Freezing and thawing stress the formulation. Agitation creates interfacial stress, and molecular work on liraglutide has traced aggregation to combined air-water and silicone-oil-water interfaces. Studies of subvisible particles in prefilled injectables have shown that drop shock alone generates particles from silicone oil and protein. Reviews of protein aggregation methodology exist because detecting these changes requires instruments rather than eyes.
The consequence is uncomfortable and worth stating without hedging: a preparation can be degraded and look entirely normal. Clarity is not a pass, and there is no home test.
Transit is a risk factor before the vial is ever handled
FDA states that injectable GLP-1 drugs require refrigeration as indicated in their package inserts, has received complaints that some compounded GLP-1 products arrived warm or with inadequate ice packs, and recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration. Distance, weather and carrier delays all sit outside the patient’s control, which makes the delivery inspection more consequential for mail-order supply than for a product collected from a local counter.
| Risk factor | What it changes | Who carries the most exposure |
|---|---|---|
| Pharmacy-specific formulation | Degradation pathways and assigned dating | Anyone switching source mid-treatment |
| Preserved versus single-entry vial | Whether repeated puncture was ever contemplated | Patients rationing a container to stretch supply |
| Reconstituted versus ready to use | When the clock starts and how it runs | Anyone assuming powder and solution behave alike |
| Heat, freezing, agitation | Chemical degradation and aggregation, invisible | Long shipping routes, summer deliveries, travel |
| Unlicensed or research-labeled sourcing | Ingredient identity and sterility unknown | Buyers chasing the lowest price online |
| Cost pressure at refill time | Improvised use of product past its date | Cash payers between shipments |
Where the product came from changes everything downstream
Supply outside a licensed pharmacy carries risks that dating cannot address. FDA has warned companies illegally selling unapproved drugs containing semaglutide, tirzepatide or retatrutide labeled for research purposes or not for human consumption, sold to consumers with dosing instructions. The agency has stated that retatrutide and cagrilintide cannot be used in compounding under federal law. On ingredient identity, FDA names semaglutide sodium and semaglutide acetate as different active ingredients from those in the approved drugs, an illustration of how a substituted form can move through a supply chain unnoticed. An import alert now covers GLP-1 active ingredients with potential quality concerns.
Market surveillance research on semaglutide sold online without a prescription found quality and seller conduct problems across the sample. None of that is fixed by a date printed on a carton.
Cost pressure is a genuine risk factor
Ignoring the money makes the safety argument weaker, not stronger. People stretch vials because refills are expensive and shipments do not always line up with dating. Choosing a supervised tirzepatide provider does not remove the dating question, but it puts a named pharmacy and a reachable prescriber behind the answer, which an anonymous vendor cannot. Noom and Hims & Hers publish their program pricing, and LillyDirect offers the approved product directly to eligible patients, so the real monthly cost can be compared before a gap appears rather than during one.
Patient-side factors that raise the stakes
Contamination risk is not distributed evenly. People who are immunocompromised, who have diabetes, or who inject in less controlled settings carry more consequence from the same event. Administration itself is a documented source of harm in this drug class, with published cross-sectional work examining adverse events tied to administering GLP-1 receptor agonists. Combining an uncertain product with an uncertain technique compounds two separate problems.
Frequently asked questions
Why can two vials of the same drug carry different dates?
Because they are not the same preparation. Concentration, buffer, pH, excipients, container and preservative status all differ between pharmacies, and each of those affects how the product behaves over time. The pharmacy dates what it actually made, which is the only preparation the date describes.
Does a cool package mean the product is fine?
It means one risk did not clearly materialize. Temperature history during a multi-day route is not knowable from the final state of the box, and degradation is not visible in the liquid. FDA advises against using injectable GLP-1 product that arrives warm, which is a floor rather than a certification.
Is compounded product inherently unsafe?
No. Compounding serves patients whose needs cannot be met by an approved drug, and licensed pharmacies operate under real oversight. The accurate statement is narrower: compounded drugs are not FDA-approved, quality has not been reviewed before marketing, and the safeguards therefore depend on the specific pharmacy involved.
Does freezing extend usable life?
Freezing is a stress on peptide formulations, not a preservation strategy, and nothing about a compounded preparation supports improvising with it. The conditions a product tolerates are the ones its pharmacy specified, and questions about them belong to that pharmacy.
What single factor most changes the risk profile?
Whether a licensed pharmacy and an identifiable prescriber stand behind the vial. That determines whether dating, formulation records, lot tracing and a recall path exist at all. Every other variable is easier to reason about once that one is settled.
